STOCK TITAN

[144] Tenaya Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. (TNYA) filed a Form 144 notice for a proposed sale of 5,053 shares of its common stock through Morgan Stanley Smith Barney Operations Department, with an aggregate market value of $6,331.41. The filing lists total shares outstanding as 162,976,102 and an approximate sale date of 08/18/2025. The securities to be sold were acquired as Restricted Stock Units from the issuer on 08/18/2025, showing an acquired amount of 13,750 units and a payment date of 08/18/2025. The filer reports no sales in the past three months and includes the standard representation about nonpublic material information.

Tenaya Therapeutics, Inc. (TNYA) ha depositato un avviso Form 144 per la proposta di vendita di 5.053 azioni del proprio capitale sociale tramite Morgan Stanley Smith Barney Operations Department, per un valore di mercato complessivo di $6.331,41. Il deposito indica un totale di azioni in circolazione pari a 162.976.102 e una data approssimativa di vendita il 18/08/2025. I titoli da vendere sono stati acquisiti come Restricted Stock Units dall’emittente in data 18/08/2025, con un ammontare acquisito di 13.750 unità e una data di pagamento il 18/08/2025. Il dichiarante segnala l’assenza di vendite negli ultimi tre mesi e include la consueta dichiarazione relativa all’assenza di informazioni materiali non pubbliche.

Tenaya Therapeutics, Inc. (TNYA) presentó un aviso Form 144 para una venta propuesta de 5.053 acciones de su capital social a través de Morgan Stanley Smith Barney Operations Department, con un valor de mercado agregado de $6.331,41. La presentación indica un total de acciones en circulación de 162.976.102 y una fecha aproximada de venta del 18/08/2025. Los valores a venderse fueron adquiridos como Restricted Stock Units del emisor el 18/08/2025, mostrando una cantidad adquirida de 13.750 unidades y una fecha de pago del 18/08/2025. El declarante informa que no ha realizado ventas en los últimos tres meses e incluye la representación estándar sobre la ausencia de información material no pública.

Tenaya Therapeutics, Inc.(TNYA)는 Morgan Stanley Smith Barney Operations Department를 통해 보통주 5,053주를 매도할 예정임을 알리는 Form 144를 제출했으며, 총 시가 가치는 $6,331.41입니다. 제출서에는 총 발행 주식 수를 162,976,102주로 기재하고 있으며, 대략적인 매도 예정일은 2025-08-18로 되어 있습니다. 매도될 증권은 발행사로부터 Restricted Stock Units 형태로 2025-08-18에 취득된 것으로, 취득 수량은 13,750단위이고 지급일도 2025-08-18입니다. 제출자는 최근 3개월 내 매도 사실이 없음을 보고하고 비공개 주요 정보가 없다는 표준 진술을 포함하고 있습니다.

Tenaya Therapeutics, Inc. (TNYA) a déposé un avis Form 144 concernant une vente proposée de 5 053 actions ordinaires via Morgan Stanley Smith Barney Operations Department, pour une valeur marchande totale de 6 331,41 $. Le dépôt indique un nombre total d'actions en circulation de 162 976 102 et une date approximative de vente au 18/08/2025. Les titres à vendre ont été acquis sous forme de Restricted Stock Units de l'émetteur le 18/08/2025, avec un montant acquis de 13 750 unités et une date de paiement le 18/08/2025. Le déclarant signale l'absence de ventes au cours des trois derniers mois et inclut la déclaration standard concernant l'absence d'informations matérielles non publiques.

Tenaya Therapeutics, Inc. (TNYA) hat eine Form-144-Mitteilung für den geplanten Verkauf von 5.053 Stammaktien über die Morgan Stanley Smith Barney Operations Department eingereicht, mit einem Gesamtmarktwert von $6.331,41. Die Einreichung nennt die insgesamt ausstehenden Aktien mit 162.976.102 und ein ungefähres Verkaufsdatum 18.08.2025. Die zu veräußernden Wertpapiere wurden am 18.08.2025 als Restricted Stock Units vom Emittenten erworben, der erworbene Betrag beträgt 13.750 Einheiten und das Zahlungsdatum ist 18.08.2025. Der Meldende berichtet über keine Verkäufe in den letzten drei Monaten und fügt die übliche Erklärung zur Abwesenheit nichtöffentlicher, wesentlicher Informationen bei.

Positive
  • Form 144 filed to disclose proposed sale, satisfying Rule 144 reporting requirements
  • Securities originate from Restricted Stock Units, and acquisition/payment dates are stated
Negative
  • Filer and issuer identifying information are not provided in the content supplied
  • No context on filer relationship or trading plan dates is included, limiting governance transparency

Insights

TL;DR: Small planned sale of RSU-derived shares filed under Rule 144; minimal market impact expected based on stated quantities.

The Form 144 discloses a proposed brokered sale of 5,053 common shares with an aggregate market value of $6,331.41, originating from 13,750 restricted stock units granted and acquired on 08/18/2025. The filing confirms no reported sales in the prior three months and lists total outstanding shares as 162,976,102. This notice is procedural under Rule 144 to permit public resale and includes the required representation about material nonpublic information. There are no earnings, debt, or other financial metrics provided in this filing to assess broader company financials.

TL;DR: Form 144 documents an insider or affiliate resale plan step; disclosure is routine and complies with Rule 144 formality.

The filing identifies the securities as acquired via issuer-granted restricted stock units and signals intent to sell through Morgan Stanley Smith Barney. The document contains the standard attestation that the seller is unaware of undisclosed material adverse information. No information about the filer identity, specific insider role, or any trading plan dates is provided in the content. As presented, the notice fulfills Rule 144 reporting requirements but provides limited governance context due to omitted filer and issuer identifying details in the submitted content.

Tenaya Therapeutics, Inc. (TNYA) ha depositato un avviso Form 144 per la proposta di vendita di 5.053 azioni del proprio capitale sociale tramite Morgan Stanley Smith Barney Operations Department, per un valore di mercato complessivo di $6.331,41. Il deposito indica un totale di azioni in circolazione pari a 162.976.102 e una data approssimativa di vendita il 18/08/2025. I titoli da vendere sono stati acquisiti come Restricted Stock Units dall’emittente in data 18/08/2025, con un ammontare acquisito di 13.750 unità e una data di pagamento il 18/08/2025. Il dichiarante segnala l’assenza di vendite negli ultimi tre mesi e include la consueta dichiarazione relativa all’assenza di informazioni materiali non pubbliche.

Tenaya Therapeutics, Inc. (TNYA) presentó un aviso Form 144 para una venta propuesta de 5.053 acciones de su capital social a través de Morgan Stanley Smith Barney Operations Department, con un valor de mercado agregado de $6.331,41. La presentación indica un total de acciones en circulación de 162.976.102 y una fecha aproximada de venta del 18/08/2025. Los valores a venderse fueron adquiridos como Restricted Stock Units del emisor el 18/08/2025, mostrando una cantidad adquirida de 13.750 unidades y una fecha de pago del 18/08/2025. El declarante informa que no ha realizado ventas en los últimos tres meses e incluye la representación estándar sobre la ausencia de información material no pública.

Tenaya Therapeutics, Inc.(TNYA)는 Morgan Stanley Smith Barney Operations Department를 통해 보통주 5,053주를 매도할 예정임을 알리는 Form 144를 제출했으며, 총 시가 가치는 $6,331.41입니다. 제출서에는 총 발행 주식 수를 162,976,102주로 기재하고 있으며, 대략적인 매도 예정일은 2025-08-18로 되어 있습니다. 매도될 증권은 발행사로부터 Restricted Stock Units 형태로 2025-08-18에 취득된 것으로, 취득 수량은 13,750단위이고 지급일도 2025-08-18입니다. 제출자는 최근 3개월 내 매도 사실이 없음을 보고하고 비공개 주요 정보가 없다는 표준 진술을 포함하고 있습니다.

Tenaya Therapeutics, Inc. (TNYA) a déposé un avis Form 144 concernant une vente proposée de 5 053 actions ordinaires via Morgan Stanley Smith Barney Operations Department, pour une valeur marchande totale de 6 331,41 $. Le dépôt indique un nombre total d'actions en circulation de 162 976 102 et une date approximative de vente au 18/08/2025. Les titres à vendre ont été acquis sous forme de Restricted Stock Units de l'émetteur le 18/08/2025, avec un montant acquis de 13 750 unités et une date de paiement le 18/08/2025. Le déclarant signale l'absence de ventes au cours des trois derniers mois et inclut la déclaration standard concernant l'absence d'informations matérielles non publiques.

Tenaya Therapeutics, Inc. (TNYA) hat eine Form-144-Mitteilung für den geplanten Verkauf von 5.053 Stammaktien über die Morgan Stanley Smith Barney Operations Department eingereicht, mit einem Gesamtmarktwert von $6.331,41. Die Einreichung nennt die insgesamt ausstehenden Aktien mit 162.976.102 und ein ungefähres Verkaufsdatum 18.08.2025. Die zu veräußernden Wertpapiere wurden am 18.08.2025 als Restricted Stock Units vom Emittenten erworben, der erworbene Betrag beträgt 13.750 Einheiten und das Zahlungsdatum ist 18.08.2025. Der Meldende berichtet über keine Verkäufe in den letzten drei Monaten und fügt die übliche Erklärung zur Abwesenheit nichtöffentlicher, wesentlicher Informationen bei.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Tenaya Therapeutics' (TNYA) Form 144 disclose?

The filing discloses a proposed sale of 5,053 common shares with an aggregate market value of $6,331.41, to be sold via Morgan Stanley on 08/18/2025.

Where did the shares proposed for sale come from in the Form 144?

The shares were acquired as Restricted Stock Units from the issuer on 08/18/2025, with 13,750 units shown as acquired.

Does the filing report any securities sold in the past three months?

No. The Form 144 content states "Nothing to Report" for securities sold during the past three months.

What is the approximate date of the proposed sale in the Form 144?

The approximate date of sale listed is 08/18/2025.

Which broker is named in the Form 144 for the proposed sale?

The broker named is Morgan Stanley Smith Barney Operations Department at the Purchase, NY address shown in the filing.

Does the Form 144 include a representation about material nonpublic information?

Yes. The person for whose account the securities are to be sold represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Tenaya Therapeutics, Inc.

NASDAQ:TNYA

TNYA Rankings

TNYA Latest News

TNYA Latest SEC Filings

TNYA Stock Data

202.09M
161.35M
0.7%
22.21%
6.51%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO